

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/756,153
Filing Date	1-13-2004
First Named Inventor	Johnson et al.
Art Unit	1644
Examiner Name	Szperka, Michael Edward
Attorney Docket Number	13783-105015

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	A1	US-5,219,728	06-15-1993		
	A2	US- 5,767,077	06-16-1998		
	A3	US- 5,976,831	11-02-1999		
	A4	US- 5,998,166	12-07-1999		
	A5	US- 6,294,347	09-25-2001		
	A6	US- 6,444,789 B1	09-03-2002		
	A7	US- 5,451,669	09-19-1995		
	A8	US- 5,985,599	11-16-1999		
	A9	US- 5,116,964	05-26-1992		
	A10	US- 5,155,027	10-13-1992		
	A11	US- 5,428,130	06-27-1995		
	A12	US- 5,641,863	06-24-1997		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B1	EP 0 131 142	01-16-1985	Gambro Lundia AB		
	B2	EP 0 343 950 B1	11-29-1989	Applied Research Systems ARS Holding N.V.		
	B3	WO 96/34953	11-07-1996	Applied Research Systems ARS Holdings N.V.		
	B4	EP 0791 653 A1	08-27-1997	Schering Biotech Corp.		
	B5	WO 99/40117	08-12-1999	Ilexus Pty. Limited		
	B6	EP 0 319 307	06-07-1989	Schering Biotech Corp.		
	B7	WO 91/06570	05-16-1991	The University of Melbourne		
	B8	EP 1 006 183 A1	06-07-2000	Max-Planck-Gesellschaft zur Foerderung Der Wissenschaften E.V.		
	B9	WO 00/32767	06-08-2000	Max-Planck-Gesellschaft zur Foerderung Der Wissenschaften E.V.		
	B10	WO 88/03172	05-05-1988	Memorial Sloan-Kettering Cancer Center		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	10/756,153
Filing Date	1-13-2004
First Named Inventor	Johnson et al.
Art Unit	1644
Examiner Name	Szperka, Michael Edward
Attorney Docket Number	13783-105015

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C6	Bouhlal et al., "Soluble CD16 Inhibits CR3 (CD11b/CD18)-Mediated Infection of Monocytes/Macrophages by Opsonized Primary R5 HIV-11," <i>Journal of Immunology</i> , 166: 3377-3383, 2001.	
	C7	Galon et al., "Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16)," <i>European Journal of Immunology</i> , 28(7): 2101-2107, 1998.	
	C8	Gavin et al., "Recombinant soluble Fc gamma RII inhibits immune complex precipitation," <i>Clinical Experimental Immunology</i> , 102(3): 620-625, 1995.	
	C9	Hibbs et al., "Membrane-Proximal Ig-like Domain of FcγRIII (CD16) Contains Residues Critical for Ligand Binding," <i>Journal of Immunology</i> , 152(9): 4466-4474, 1994.	
	C10	Hoover et al., "Autoregulatory Circuits in Myeloma Tumor Cell Cytotoxicity Mediated by Soluble CD16," <i>Journal of Clinical Investigation</i> , 95(1): 241-247, 1995.	
	C11	Ierino et al., "Recombinant Soluble Human FcγRII: Production, Characterization, and Inhibition of the Arthus Reaction," <i>Journal of Experimental Medicine</i> , 178: 1617-1628, 1993.	
	C12	Li et al., "Recombinant CD16A-Ig forms a homodimer and cross-blocks the ligand binding functions of neutrophil and monocyte Fcγ receptors," <i>Molecular Immunology</i> , 38: 527-538, 2001.	
	C13	Simpson et al., "Soluble FcR Block Suppressor T Cell Activity at Low Concentration <i>in Vitro</i> Allowing Isotype-Specific Antibody Production," <i>Cellular Immunology</i> , 167(1): 122-128, 1996.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.